Andreas is CEO of Ventura BioMed, a venture capital investor in early-stage biotech companies developing pioneering technologies and innovative therapies. Andreas has more than 20 years of executive management experience in the life sciences industry and launched six biotechnology companies. Until recently, he was managing director of SciRhom, a developer of therapeutic antibodies.
Further professional stations include CEO positions at RSP Systems (a Danish medical device company focusing on non-invasive diagnostics), Kinaxo (a proteomics service provider sold to Evotec in 2011) and NEO New Oncology (a cancer diagnostics company sold to Siemens Healthcare in 2016). Andreas holds a Ph.D. in Chemistry from the Ludwig-Maximilians-University in Munich.